{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:08:31Z","timestamp":1784045311093,"version":"3.55.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Patients with acute myocardial infarction (MI) and atrial fibrillation (AF) present challenges in antithrombotic treatment. Effects of newer treatment strategies on outcomes remain uncertain. We assessed implementation of antithrombotic treatment and occurrence of cardiovascular (CV) events and major bleeding in patients with MI and AF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Nationwide data from SWEDEHEART and national health registries were used to identify 71 513 survivors of an acute MI with AF between 2000 and 2021. Changes in antithrombotic therapies over time in 2-year cohorts were analysed, and associations with 1-year outcomes were assessed. The outcomes were ischaemic stroke or systemic embolism, MI, major bleeding, CV mortality and all-cause mortality. Logistic regression was used to standardize for changes in patient characteristics and treatment over time. Oral anticoagulant use increased from 21% in 2000\u20132001 to 75% in 2020\u20132021, largely due to adoption of direct oral anticoagulants (DOACs) after the first DOAC approval in 2011, most often combined with a single antiplatelet. Over time, particularly in the last decade, 1-year risk of ischaemic stroke or systemic embolism declined from 6.0% to 2.1%, and CV mortality decreased from 19.8% to 10.5%. Major bleeding increased from 3.9% to 7.6% in 2014\u20132015, then declined to 6.4% in 2020\u20132021, simultaneously with adoption of single rather than dual antiplatelet therapy in combination with DOAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Between 2000 and 2021, among patients with MI and AF, we observed reductions in 1-year risks of ischaemic stroke or systemic embolism and CV mortality, occurring during a period of increased prescription of oral anticoagulants, particularly DOACs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key question and findings<\/jats:title>\n                    <jats:p>Key Question<\/jats:p>\n                    <jats:p>Have recent clinical trial findings on antithrombotic therapy in patients with myocardial infarction and concomitant atrial fibrillation been implemented, and have they resulted in any improvement in 1-year outcomes?<\/jats:p>\n                    <jats:p>Key Finding<\/jats:p>\n                    <jats:p>In patients with myocardial infarction and atrial fibrillation, we observed substantial reductions in 1-year risks of ischaemic stroke or systemic embolism and cardiovascular mortality, associated with increased prescribing of oral anticoagulants, particularly DOACs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvag027","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:41:45Z","timestamp":1776944505000},"page":"247-257","source":"Crossref","is-referenced-by-count":0,"title":["Implementation of novel antithrombotic treatment strategies and outcome improvements in patients with myocardial infarction and atrial fibrillation over 20 years: a nationwide cohort study"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2249-4548","authenticated-orcid":false,"given":"Christian","family":"Losciale","sequence":"first","affiliation":[{"name":"Department of Medicine, Nyk\u00f6pings Lasarett , 611 39 Nyk\u00f6ping ,","place":["Sweden"]},{"name":"Department of Medical Sciences, Cardiology, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Lindhagen","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0378-6531","authenticated-orcid":false,"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]},{"name":"Uppsala Clinical Research Center, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1695-379X","authenticated-orcid":false,"given":"Tomas","family":"Jernberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute , 182 88 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1415-7178","authenticated-orcid":false,"given":"Joakim","family":"Alfredsson","sequence":"additional","affiliation":[{"name":"Department of Health, Medicine and Caring Sciences, Link\u00f6ping University , 581 83 Link\u00f6ping ,","place":["Sweden"]},{"name":"Department of Cardiology, Link\u00f6ping University , 581 83 Link\u00f6ping ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9969-3921","authenticated-orcid":false,"given":"Jonas","family":"Oldgren","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]},{"name":"Uppsala Clinical Research Center, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2480-9547","authenticated-orcid":false,"given":"Gorav","family":"Batra","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]},{"name":"Uppsala Clinical Research Center, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"2026071411423016900_pvag027-B1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-077209","article-title":"Temporal trends in lifetime risks of atrial fibrillation and its complications between 2000 and 2022: Danish, nationwide, population based cohort study","volume":"385","author":"Vinter","year":"2024","journal-title":"BMJ"},{"key":"2026071411423016900_pvag027-B2","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020163","article-title":"Trends in cardiovascular mortality related to atrial fibrillation in the United States, 2011 to 2018","volume":"10","author":"Tanaka","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026071411423016900_pvag027-B3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"2026071411423016900_pvag027-B4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjmed.2006.07.034","article-title":"Death and disability from warfarin-associated intracranial and extracranial hemorrhages","volume":"120","author":"Fang","year":"2007","journal-title":"Am J Med"},{"key":"2026071411423016900_pvag027-B5","doi-asserted-by":"crossref","first-page":"j5058","DOI":"10.1136\/bmj.j5058","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"L\u00f3pez-L\u00f3pez","year":"2017","journal-title":"BMJ"},{"key":"2026071411423016900_pvag027-B6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2026071411423016900_pvag027-B7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2026071411423016900_pvag027-B8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2026071411423016900_pvag027-B9","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2026071411423016900_pvag027-B10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet Lond Engl"},{"key":"2026071411423016900_pvag027-B11","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial","volume":"367","author":"ACTIVE Writing Group of the ACTIVE Investigators","year":"2006","journal-title":"Lancet Lond Engl"},{"key":"2026071411423016900_pvag027-B12","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet Lond Engl"},{"key":"2026071411423016900_pvag027-B13","first-page":"204","article-title":"Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention\/stenting: a systematic review and meta-analysis","volume":"29","author":"Andrade","year":"2013","journal-title":"Can J Cardiol"},{"key":"2026071411423016900_pvag027-B14","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"key":"2026071411423016900_pvag027-B15","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2026071411423016900_pvag027-B16","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"2026071411423016900_pvag027-B17","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"2026071411423016900_pvag027-B18","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ahj.2014.12.006","article-title":"An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)","volume":"169","author":"Gibson","year":"2015","journal-title":"Am Heart J"},{"key":"2026071411423016900_pvag027-B19","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2026071411423016900_pvag027-B20","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"2026071411423016900_pvag027-B21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ahj.2025.04.028","article-title":"Data quality assessment in the SWEDEHEART registry: insights from serial audits on completeness and accuracy","volume":"288","author":"Leosdottir","year":"2025","journal-title":"Am Heart J"},{"key":"2026071411423016900_pvag027-B22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2026071411423016900_pvag027-B23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10840-017-0308-9","article-title":"Atrial fibrillation is associated with sudden cardiac death: a systematic review and meta-analysis","volume":"51","author":"Rattanawong","year":"2018","journal-title":"J Interv Card Electrophysiol Int J Arrhythm Pacing"},{"key":"2026071411423016900_pvag027-B24","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCOUTCOMES.108.842146","article-title":"Improved clinical outcome after acute myocardial infarction in hospitals participating in a Swedish quality improvement initiative","volume":"2","author":"Carlhed","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026071411423016900_pvag027-B25","first-page":"1722","article-title":"Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five western European countries","volume":"23","author":"Komen","year":"2021","journal-title":"Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag027\/68165685\/pvag027.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/4\/247\/68165685\/pvag027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/4\/247\/68165685\/pvag027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:42:40Z","timestamp":1784043760000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/4\/247\/8663037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,27]]},"published-print":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag027","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,4,27]]}}}